Canada OKs Osiris drug; initial branch dungeon therapy

<p>BOSTON (Reuters) Osiris Therapeutics Inc pronounced on Thursday that Canadian health regulators have authorized a diagnosis for strident graft-versus horde illness in children, creation it a initial branch dungeon drug to be authorized for a systemic disease anywhere in a world.
Osiris shares rose 14 percent to $6.00 in extended trade after a news was announced.
Graft contra horde illness (GvHD) is a potentially lethal snarl from a bone pith transplant, when newly ingrained cells conflict a patients body. Symptoms operation from abdominal pain and skin unreasonable to hair loss, hepatitis, lung and digestive tract disorders, jaundice and vomiting.
The illness kills adult to 80 percent of children affected, Osiris said. To date there have been no authorized treatments for a disease. Canadian authorities authorized a therapy, Prochymal, for use in children who have unsuccessful to respond to steroids.
Prochymal was authori...